Skip to main content
NewslettersWatchlist

Guardant Health Inc(GH-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low16.39
Day High16.78
Open:16.56
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
PR Newswire
Multiple Myeloma Therapeutics Market Expected to Reach $4.26 Billion in 2030
Motley Fool
1 Beaten-Down Healthcare Stock to Buy and Hold For 10 Years
Motley Fool
Which Is the Better Cancer-Testing Healthcare Stock: Exact Sciences or Guardant Health?
Motley Fool
Why Guardant Health Stock Jumped 15% This Week
Motley Fool
2 Cathie Wood Stocks to Buy and Hold for 10 Years
Barchart
A Hidden AI Stock to Add to Your Portfolio
PR Newswire
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
Barchart
Stock Index Futures Move Lower as U.S. Debt Ceiling Uncertainty Weighs on Sentiment, PMI Data in Focus
Motley Fool
Why Shares of Guardant Health Jumped This Week
Motley Fool
Why Guardant Health's Shares Climbed This Week
PressReach
A New Groundbreaking Tool to Detect Colon Cancer Earlier
Business Wire
Guardant Health Announces Additions to Leadership Team
Business Wire
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
PressReach
New Artificial Intelligence Tool Can Diagnose Colon Cancer
Business Wire
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
Business Wire
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
Business Wire
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
Business Wire
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
Business Wire
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
Business Wire
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
Business Wire
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
Business Wire
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Motley Fool
2 Stocks That Could Rebound and Rise 30% or More in 2023
Motley Fool
2 Potentially Explosive Growth Stocks Down 30% or More to Buy for the Next Bull Market
Business Wire
Musa Tariq Joins Guardant Health Board of Directors
Business Wire
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
Business Wire
Guardant Health to Participate in Upcoming March Investor Conferences
Business Wire
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Business Wire
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Business Wire
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
Business Wire
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina

Profile

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. It launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant Health Inc. is based in REDWOOD CITY, United States.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.